Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.9616 -0.0017 (-0.18%)
Streaming Delayed Price Updated: 11:07 AM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
2 Stocks That Could Double Your Money in 2023
These biotechs could crush the market, but there is more to the story. 
Via The Motley Fool
bluebird bio Sells Second Priority Review Voucher for $95 Million
From bluebird bio, Inc.
Via Business Wire
Newly Approved Drugs In US Command Over $200,000 On An Average
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003. 
Via Benzinga
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
From bluebird bio, Inc.
Via Business Wire
2 Risky Stocks That Could Soar in 2023
These "exciting" companies aren't for everyone. 
Via The Motley Fool
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
Both stocks have fallen brutally this year, but only one has a chance to recover soon. 
Via The Motley Fool
After Doubling in the Past 6 Months, Is This Stock a Buy?
This company has had a solid year, but there is still plenty of work ahead. 
Via The Motley Fool
FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol
Via Benzinga
BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment
In a counterintuitive move, traders are selling BLUE stock even as Bluebird Bio claims to be on track with its sickle cell disease treatment. 
Via InvestorPlace
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
From bluebird bio, Inc.
Via Business Wire
Looking Into bluebird bio's Return On Capital Employed
Via Benzinga
Analyst Ratings for bluebird bio
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: 
Via Benzinga
Recap: bluebird bio Q3 Earnings
bluebird bio (NASDAQ:BLUE) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting
Via Benzinga
Why Bluebird Bio Stock Crushed the Market Today
The company looks set to continue its good momentum in the early part of next year. 
Via The Motley Fool
New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
From bluebird bio inc.
Via Business Wire
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via TheNewswire.com
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Why CSL Ltd Stock Could Be Worth a Look
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment. 
Via MarketBeat
Exposures Product Safety
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Via Benzinga
bluebird bio Sells Priority Review Voucher for $102 Million
From bluebird bio, Inc.
Via Business Wire
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
Via Benzinga
Where Will Editas Medicine Be in 1 Year?
The company could continue lagging the market for a while. 
Via The Motley Fool
2 Growth Stocks That Could Double in 2023
Both are lagging the market this year. 
Via The Motley Fool
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Better Buy: CRISPR Therapeutics vs. Bluebird Bio
These two companies have performed almost equally poorly on the stock market in the past year. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.